

Title: Th1-related cytokines, chemokines and products in AD

Dates: 6/6/2017 – 6/6/2018

Locations: <http://www.mycme.com/itch-module-1---causes-of-barrier-dysfunction-and-therapeutic-targets-in-atopic-dermatitis/activity/4741/>

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Identify new and emerging biologic treatment options for moderate-to-severe AD
- Describe the mechanism of action and biologic rationale of these novel biologic agents
- Evaluate the benefits and risks of these novel agents, including their efficacy, safety, and attributes, in the treatment of patients with moderate-to-severe AD
- Apply a multidisciplinary approach to enhance the assessment, management, and long-term care of AD patients
- Develop strategies to counsel patients and their families for improved adherence

Target Audience

The educational design of this activity addresses the needs of dermatologists, immunologists, allergists, pediatricians, and primary care practitioners involved in the treatment and management of patients with atopic dermatitis.

Program Overview

The ITCH Digital Library is an interactive, flexible series of mini-modules grouped into learning categories:

Immune and Barrier Dysfunction Toolkit for Multidisciplinary Approach to Patient Care Cases Hope on the Horizon (emerging therapies)

The program focuses on the identified educational needs of both specialists and primary care practitioners, including disease overview, differential diagnosis, referral checklists, treatment plans for ongoing management between specialist visits, etc. Learners can customize their learning by completing modules that align with their educational needs.

Faculty

Robert Sidbury, MD MPH
Department of Pediatrics - Division Chief
Seattle Children's Hospital
Associate Professor, Adjunct
Division of Dermatology
Department of Medicine
University of Washington
Seattle, WA

Lynda Schneider, MD
Director, Allergy Program
Boston Children's Hospital
Professor of Pediatrics
Harvard Medical School
Boston, MA

Timothy Berger, MD
Dermatologist
University of California San Francisco Medical Center
Professor of Clinical Dermatology
University of California San Francisco
San Francisco, CA

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and Integritas. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement

Clinical and Patient Educators Association designates this enduring activity for a maximum of 0.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

CPEA requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.